TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence

Stress Urinary Incontinence Clinical Trial

Official title:

An Evaluation of the GYNECARE TVT-SECUR* System (Tension-free Support for Incontinence) for the Treatment of Stress Urinary Incontinence *Trademark

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00463554
• Other study ID #: 300-05-002
• Status: Completed
• Start date: April 1, 2006
• Est. completion date: December 1, 2007

Study information

• Verified date: August 2023
• Source: Ethicon, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary objective of this study is to obtain clinical performance information on the GYNECARE TVT-SECUR* System (Tension-free Support for Incontinence) in women with stress urinary incontinence (SUI).

Description:

The primary variable for effectiveness is > 50% improvement on the subjective symptom Visual Analog Scale (VAS) at Visit 3/Week 5 (35 days post-surgery) to be accepted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 72
• Est. completion date: December 1, 2007
• Est. primary completion date: January 1, 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Must be female with objective, demonstratable signs of SUI or stress predominant mixed incontinence and requires elective, primary surgical intervention.

• Must be at least 21 years old.

• Must be postmenopausal (amenorrhea) for at least 1 year or surgically sterile (bilateral salpingo-oophorectomy or tubal ligation or otherwise be incapable of pregnancy) or has a negative pregnancy test prior to study entry and has decided to cease childbearing.

• Agrees to participate in the study, including all study related procedures and evaluations and documents this agreement by signing the IRB/EC-approved informed consent

Exclusion Criteria:

• Have any other coexistent pathology requiring concomitant surgery that may impact this procedure i.e. surgeries that involve the anterior vaginal wall (e.g. anterior colporrhaphy, diverticula, anterior Prolift) Any allowable concomitant surgery must be performed prior to the GYNECARE TVT SECUR System surgery.

• Have intrinsic sphincter deficiency (ISD) [Urethral Pressure Profile (UPP) with a maximum urethral closing pressure (MUCP) < 20cm H2O or Leak Point Pressure (LPP) < 60].

• Have an active urinary tract infection (UTI) or vaginal infection at time of surgery.

• Have a fixed urethra (< 30° mobility on Q-Tip Straining Test).

• Have had prior incontinence surgery.

• Have a post-void residual volume > 100mL.

• Have co-existent pelvic organ prolapse that is symptomatic or extends beyond the hymen.

• Have lower urinary tract pathology in the form of a fistula or diverticulum.

• Have a malignancy or with a history of malignancy within the past 5 years, except for a basal cell carcinoma that has been treated with local excision and is no longer present.

• Are on anticoagulant therapy.

• Have received an experimental drug or used an experimental medical device within 30 days prior to the planned start of treatment.

• Are deemed by the investigator as medically unfit for surgery or who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings or contraindications outlined in the GYNECARE TVT SECUR System IFU.

• Employees of the investigator or study center with direct involvement in the proposed study or other studies under the direction of that investigator or study center.

Related Conditions & MeSH terms

• Enuresis
• Stress Urinary Incontinence
• Urinary Incontinence
• Urinary Incontinence, Stress

Intervention

Device:
• GYNECARE TVT-SECUR* System
A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency

Locations

Country	Name	City	State
Finland	Helsinki University Central Hospital	Helsinki
Italy	University of Padova	Padova
United States	The Institute for Female Pelvic Medicine and Reconstructive Surgery	Allentown	Pennsylvania
United States	Good Samaritan Hospital	Cincinnati	Ohio
United States	Michigan Institute of Women's Health	Dearborn	Michigan
United States	Vanderbilt University	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Ethicon, Inc.

Countries where clinical trial is conducted

United States,  Finland,  Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical performance of TVT-SECUR*		Screening and Day 35
Secondary	Assessment of the results of the standing cough stress test		Screening, Week 5, Months 6 and 12
Secondary	Intra- and post-operative complications		Intraoperative, Week 5, Months 6 and 12
Secondary	Physician questionnaire results		Months 2 and 12
Secondary	Urodynamics		Screening, Week 5, Months 6 and 12 (post-operative optional)
Secondary	QoL measures		Screening, Week 5, Months 6 and 12
Secondary	Subject satisfaction.		Month 12
Secondary	Anesthesia		intraoperative
Secondary	Operative time		Intraoperative